Spots Global Cancer Trial Database for recurrent cancer
Every month we try and update this database with for recurrent cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Communication Strategies to Introduce Psychology Services | NCT03035448 | Malignant Neopl... | Questionnaires Video Presentat... | 18 Years - | M.D. Anderson Cancer Center | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions | NCT05045040 | End of Life Car... Advanced Cancer Recurrent Cance... | Mobile-based em... | 20 Years - | National Cancer Center, Japan | |
| Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors | NCT04889742 | Recurrent Cance... Prostate Cancer Cervical Cancer Anal Cancer Sarcoma Rectal Cancer Neuroendocrine ... Esophageal Canc... Pancreas Cancer Squamous Cell C... | loco-regional h... | 18 Years - | Charite University, Berlin, Germany | |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | NCT04326257 | Squamous Cell C... | Nivolumab+Relat... Nivolumab+Ipili... | 18 Years - | University of Pittsburgh | |
| Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions | NCT05045040 | End of Life Car... Advanced Cancer Recurrent Cance... | Mobile-based em... | 20 Years - | National Cancer Center, Japan | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Sublingual Fentanyl for the Management of Breakthrough Pain | NCT02514252 | Advanced Cancer... | Fentanyl Sublin... Questionnaires Mental Ability ... Study Diary | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | NCT03132038 | Salivary Gland ... Metastatic Canc... Recurrent Cance... | Nivolumab | 18 Years - | UNICANCER | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention | NCT02422329 | Advanced Cancer... | Questionnaires Video Fact Sheet | 18 Years - | M.D. Anderson Cancer Center | |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | NCT05958121 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA402 (Phase I... IMA402 (Phase I... IMA402 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | NCT00120939 | Breast Neoplasm... Ovarian Neoplas... Prostatic Neopl... Lung Neoplasms Gastrointestina... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | NCT02379520 | Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... | HPV Specific T ... Cytoxan Fludarabine Nivolumab | 18 Years - | Baylor College of Medicine | |
| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | NCT05626829 | Nasopharyngeal ... Recurrent Cance... | Tranilast | 18 Years - | Nanfang Hospital, Southern Medical University | |
| A Study of DB-1303 in Advanced/Metastatic Solid Tumors | NCT05150691 | HER2-positive A... | DB-1303 Pertuzumab Inje... Ritonavir Itraconazole | 18 Years - | DualityBio Inc. | |
| Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors | NCT05189054 | Stereotactic Bo... Irradiation; Re... Thoracic Tumor Recurrent Cance... | stereotacitic b... | 18 Years - 80 Years | Peking University Third Hospital | |
| Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | NCT05150457 | Refractory Soli... | BNA035 | 18 Years - | Binacea Pharma, Inc. | |
| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | NCT05626829 | Nasopharyngeal ... Recurrent Cance... | Tranilast | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | NCT03758781 | Metastatic Canc... Recurrent Cance... Solid Tumor Renal Cell Carc... Urothelial Carc... NSCLC Squamous Cell C... Non-Small Cell ... Squamous Cell C... | IRX 2 Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | NCT03758781 | Metastatic Canc... Recurrent Cance... Solid Tumor Renal Cell Carc... Urothelial Carc... NSCLC Squamous Cell C... Non-Small Cell ... Squamous Cell C... | IRX 2 Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer | NCT06103617 | Head and Neck C... Recurrent Cance... | Penicillamine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | NCT03941262 | Refractory Canc... Metastatic Canc... Recurrent Cance... Unresectable Ca... Solid Tumor, Ad... Advanced Cancer Advanced Solid ... | SNK01 Avelumab Pembrolizumab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention | NCT02422329 | Advanced Cancer... | Questionnaires Video Fact Sheet | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | NCT05990920 | Pathologically ... Refractory Canc... Metastatic Canc... Recurrent Cance... Solid Tumor, Ad... Solid Tumor Advanced Cancer Advanced Solid ... | SNK02 | 18 Years - | NKGen Biotech, Inc. | |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | NCT00262990 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | EPO906 (Patupil... doxorubicin | 18 Years - | Novartis | |
| Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | NCT00120939 | Breast Neoplasm... Ovarian Neoplas... Prostatic Neopl... Lung Neoplasms Gastrointestina... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| PREventing Second Cancers With DOSTARlimab | NCT05855811 | Recurrent Cance... Primary Cancer Second Cancer | Dostarlimab | 18 Years - | Centre Leon Berard | |
| Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome | NCT05250791 | Colorectal Canc... Quality of Life Recurrent Cance... | Lidocaine hydro... 0.9% sterile So... | 18 Years - | Imperial College London | |
| Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | NCT03132038 | Salivary Gland ... Metastatic Canc... Recurrent Cance... | Nivolumab | 18 Years - | UNICANCER | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | NCT03758781 | Metastatic Canc... Recurrent Cance... Solid Tumor Renal Cell Carc... Urothelial Carc... NSCLC Squamous Cell C... Non-Small Cell ... Squamous Cell C... | IRX 2 Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer | NCT06103617 | Head and Neck C... Recurrent Cance... | Penicillamine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04084951 | Adult Solid Tum... | SQZ-PBMC-HPV Atezolizumab Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | NCT06372574 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... | RO7617991 Tocilizumab | 18 Years - | Genentech, Inc. | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors | NCT05359445 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA401 (Phase I... IMA401 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) | NCT03891576 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Niraparib | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | NCT02098343 | Platinum Sensit... | APR-246 Carboplatin and... | 18 Years - | Aprea Therapeutics | |
| Recurrence After Whipple's (RAW) Study | NCT04596865 | Pancreatic Canc... Ampullary Cance... Bile Duct Cance... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Pancreatic Duct... Pancreatic Duct... Surgery Survivorship Recurrent Cance... Cancer Recurren... Cancer Recurren... Local Recurrenc... | Pancreaticoduod... | - | University Hospital Plymouth NHS Trust | |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | NCT05043922 | Ovarian Cancer Recurrent Cance... | CYH33 | 18 Years - | Haihe Biopharma Co., Ltd. | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors | NCT05359445 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA401 (Phase I... IMA401 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | NCT06208657 | Childhood Cance... Childhood Solid... Childhood Brain... Recurrent Cance... Refractory Canc... | Paxalisib, Irin... Pimasertib | 0 Years - 21 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | NCT00262990 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | EPO906 (Patupil... doxorubicin | 18 Years - | Novartis | |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention | NCT02422329 | Advanced Cancer... | Questionnaires Video Fact Sheet | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | NCT04421560 | Primary Central... Recurrent Cance... Refractory Canc... Relapsed Cancer | Ibrutinib Pembrolizumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | NCT00120939 | Breast Neoplasm... Ovarian Neoplas... Prostatic Neopl... Lung Neoplasms Gastrointestina... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions | NCT05045040 | End of Life Car... Advanced Cancer Recurrent Cance... | Mobile-based em... | 20 Years - | National Cancer Center, Japan | |
| PREventing Second Cancers With DOSTARlimab | NCT05855811 | Recurrent Cance... Primary Cancer Second Cancer | Dostarlimab | 18 Years - | Centre Leon Berard | |
| Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma | NCT05364905 | Oncology Endometrial Can... Advanced Cancer Recurrent Cance... Metastatic Canc... | Chemotherapy | 18 Years - 99 Years | ARCAGY/ GINECO GROUP | |
| A Study of DB-1303 in Advanced/Metastatic Solid Tumors | NCT05150691 | HER2-positive A... | DB-1303 Pertuzumab Inje... Ritonavir Itraconazole | 18 Years - | DualityBio Inc. | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | NCT05396300 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Zhejiang University | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling | NCT03760952 | Refractory Canc... Recurrent Cance... Adult Solid Tum... Neoplasms | 18 Years - | Immatics US, Inc. | ||
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | NCT05043922 | Ovarian Cancer Recurrent Cance... | CYH33 | 18 Years - | Haihe Biopharma Co., Ltd. | |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | NCT02632448 | Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc... | LY2880070 Gemcitabine | 18 Years - | Esperas Pharma Inc. | |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 | NCT03441100 | Solid Tumor, Ad... Refractory Canc... Recurrent Cance... Cancer | IMA202 Product IMADetect® | 18 Years - | Immatics US, Inc. | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | NCT05043922 | Ovarian Cancer Recurrent Cance... | CYH33 | 18 Years - | Haihe Biopharma Co., Ltd. | |
| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | NCT05626829 | Nasopharyngeal ... Recurrent Cance... | Tranilast | 18 Years - | Nanfang Hospital, Southern Medical University | |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | NCT03268382 | High-grade Sero... | APR-246 Pegylated Lipos... | 18 Years - | Aprea Therapeutics | |
| Online and Narrative Interventions for Advanced Cancer Patients | NCT00948207 | Metastatic Canc... | My Living Story My Own Resource... | 30 Years - 60 Years | University of Wisconsin, Madison | |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT05357898 | Adult Solid Tum... | SQZ-eAPC-HPV Pembrolizumab | 18 Years - | SQZ Biotechnologies | |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | NCT04326257 | Squamous Cell C... | Nivolumab+Relat... Nivolumab+Ipili... | 18 Years - | University of Pittsburgh | |
| Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma | NCT05364905 | Oncology Endometrial Can... Advanced Cancer Recurrent Cance... Metastatic Canc... | Chemotherapy | 18 Years - 99 Years | ARCAGY/ GINECO GROUP | |
| Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer | NCT04326088 | Head and Neck C... Recurrent Cance... Surgery--Compli... | Reconstruction ... Recurrent group | 20 Years - 100 Years | Chang Gung Memorial Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
